Luke Haws, DO
Family Medicine · Idaho Falls, IDNPI 1942521109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by Amgen at 35.9% of the total. Among family medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$609
- Novo Nordisk$304
- Mylan Specialty L.p.$185
- AstraZeneca$168
- Boehringer Ingelheim$163
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,030100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 144 | $1,807 |
| AbbVie(2 entities) | 31 | $609 |
| Novo Nordisk | 21 | $304 |
| Mylan Specialty L.p. | 10 | $185 |
| AstraZeneca | 12 | $168 |
| Boehringer Ingelheim | 10 | $163 |
| Astellas Pharma US Inc | 7 | $161 |
| GSK | 9 | $152 |
| Lilly USA, LLC | 12 | $151 |
| Medtronic(2 entities) | 9 | $138 |
| Johnson & Johnson | 8 | $124 |
| Novartis | 6 | $116 |
| Pfizer | 8 | $109 |
| Dexcom, Inc. | 5 | $104 |
| Edwards Lifesciences | 3 | $77 |
| Tandem Diabetes Care, Inc. | 3 | $69 |
| GE HealthCare | 2 | $59 |
| Abbott | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Boston Scientific | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Bayer | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Corcept Therapeutics | 2 | $28 |
| Kerecis Limited | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Merck | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Roche Diagnostics Corporation | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $3 |
How this compares
$5,037 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $99,016 |
| OzempicSemaglutide | 61 | $97,097 |
| XareltoRivaroxaban | 23 | $19,312 |
| MounjaroTirzepatide | 12 | $13,635 |
| RybelsusSemaglutide | 12 | $13,395 |
| MyrbetriqMirabegron | 16 | $10,456 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,560 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $7,260 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $6,741 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $4,064 |
| Duloxetine Hcl | 88 | $3,533 |
| Levothyroxine Sodium | 437 | $3,532 |
| Atorvastatin Calcium | 487 | $3,433 |
| Omeprazole | 260 | $2,744 |
| Ondansetron OdtOndansetron | 31 | $2,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $304 | $110,49273 claims |
| PfizerEliquis | $109 | $99,01679 claims |
| Johnson & JohnsonXarelto | $124 | $19,31223 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $152 | $14,30131 claims |
| Lilly USA, LLCMounjaro | $151 | $13,63512 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $10,45616 claims |
| AbbVieSynthroid | $609 | $1,67646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.
Other family medicine in Idaho Falls
- Anne BroadwayIdaho Falls$184K
- Julian de Bruyn KopsIdaho Falls$32K
- Wallace BakerIdaho Falls$13K
- Jace NebekerIdaho Falls$11K
- Barry BennettIdaho Falls$10K
- Flint PackerIdaho Falls$10K
- Boyd SouthwickIdaho Falls$10K
- Craig SteinerIdaho Falls$7K
- Brad EriksonIdaho Falls$7K
- Dallas RindfleischIdaho Falls$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.